{"product_id":"parp-inhibitor-maintenance-therapy-for-newly-diagnosed-advanced-ovarian-cancer-what-a-major-review-of-seven-trials-found","title":"PARP Inhibitor Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer: What a Major Review of Seven Trials Found","description":"\u003cp\u003eThis updated systematic review and network meta-analysis combined seven phase III randomized trials involving 3,930 patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. PARP inhibitor-based first-line maintenance therapy significantly improved progression-free survival compared with placebo, with the largest benefit in patients whose tumors had BRCA mutations or homologous recombination deficiency (HRD). No active regimen proved statistically superior to another within the connected network, and the added value of combining antiangiogenic therapy with a PARP inhibitor remains uncertain.\u003c\/p\u003e\n\n\u003ch1\u003ePARP Inhibitor Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer: What a Major Review of Seven Trials Found\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#results\"\u003eKey Findings: What the Analysis Showed\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#hrd\"\u003eResults in the HRD-Positive Population\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#brcam\"\u003eResults in the BRCA-Mutated Population\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#other-groups\"\u003eResults in Other Molecular Groups\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#bevacizumab\"\u003eDoes Prior Bevacizumab Change the Benefit?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#safety\"\u003eSafety Findings\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Questions to Ask Your Care Team\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn an analysis of seven phase III trials involving 3,930 patients, PARP inhibitor-based first-line maintenance significantly improved progression-free survival compared with placebo in newly diagnosed advanced ovarian cancer.\u003c\/li\u003e\n\u003cli\u003eThe largest progression-free survival benefit was seen in patients whose tumors had BRCA mutations or homologous recombination deficiency (HRD); benefit in homologous recombination proficient (HRP) tumors was inconsistent.\u003c\/li\u003e\n\u003cli\u003eNo active regimen proved statistically superior to another within the connected network, and the added value of combining antiangiogenic therapy with a PARP inhibitor remains uncertain.\u003c\/li\u003e\n\u003cli\u003ePARP inhibitor monotherapy increased grade 3 or higher adverse events compared with placebo; comparative safety of combination regimens was uncertain due to sparse data.\u003c\/li\u003e\n\u003cli\u003eKnowing your BRCA mutation and HRD status is important because these biomarkers help identify which maintenance strategy is most likely to benefit you.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eOvarian cancer remains one of the most lethal gynecologic cancers worldwide. Most patients already have advanced-stage disease when they are diagnosed.\u003c\/p\u003e\n\n\u003cp\u003eThe standard initial treatment is primary cytoreductive surgery (surgery to remove as much tumor as possible) followed by platinum-based chemotherapy. Most patients do respond to this treatment at first. However, most patients eventually experience a return of the disease (recurrence) despite an initial complete or partial response.\u003c\/p\u003e\n\n\u003cp\u003eBecause of this, researchers have focused on optimizing first-line maintenance therapy. Maintenance therapy is treatment given after the initial chemotherapy response, with the goal of prolonging the time before the cancer grows or returns.\u003c\/p\u003e\n\n\u003cp\u003ePARP inhibitors have substantially changed the first-line maintenance landscape. PARP stands for poly(ADP-ribose) polymerase, a protein that helps cancer cells repair their DNA. PARP inhibitors work through a concept called synthetic lethality. In simple terms, these drugs are particularly effective in tumors that already have impaired DNA repair through a pathway called homologous recombination repair. This group especially includes tumors with BRCA1 or BRCA2 mutations or broader homologous recombination deficiency (HRD).\u003c\/p\u003e\n\n\u003cp\u003eSeveral pivotal randomized trials have shown that PARP inhibitor maintenance significantly prolongs progression-free survival (PFS) in the first-line setting. PFS is the time from treatment until the cancer grows or spreads. The greatest benefit has generally been seen in BRCA-mutated (BRCAm) and HRD-positive disease. In contrast, the benefit in homologous recombination proficient (HRP) tumors has been less consistent and remains clinically controversial.\u003c\/p\u003e\n\n\u003cp\u003eAntiangiogenic therapy, which blocks the growth of new blood vessels that feed tumors, has also been incorporated into first-line treatment and maintenance strategies for selected patients. Combining PARP inhibition with antiangiogenic therapy has a biologic rationale. Blocking the vascular endothelial growth factor pathway may cause tumor hypoxia (low oxygen levels in the tumor) and suppress homologous recombination repair. This could make tumors more sensitive to PARP inhibition.\u003c\/p\u003e\n\n\u003cp\u003eClinical evidence for PARP inhibitor plus antiangiogenic maintenance has expanded the available treatment options. However, whether combination therapy provides extra benefit over PARP inhibitor monotherapy across molecularly defined subgroups remains uncertain. This uncertainty matters because combination therapy may increase treatment burden and toxicity.\u003c\/p\u003e\n\n\u003cp\u003eAs the number of available maintenance strategies has expanded, treatment selection has become increasingly complex. The 2026 National Comprehensive Cancer Network (NCCN) Guidelines for ovarian, fallopian tube, and primary peritoneal cancers emphasize a biomarker-directed approach to first-line maintenance therapy. In this approach, BRCA mutation status, HRD status, and prior or concurrent bevacizumab exposure are key determinants of treatment choice.\u003c\/p\u003e\n\n\u003cp\u003eHowever, direct comparative evidence among active maintenance regimens remains limited. This gap is especially relevant when choosing between PARP inhibitor monotherapy and PARP inhibitor–antiangiogenic combinations. The gap also matters when applying maintenance therapy to clinically important subgroups, such as HRD-positive non-BRCAm disease and HRP disease.\u003c\/p\u003e\n\n\u003cp\u003ePrevious meta-analyses have confirmed the overall benefit of PARP inhibitor maintenance in newly diagnosed advanced ovarian cancer. More recently, Zhang and colleagues conducted a network meta-analysis evaluating multiple PARP inhibitors in this setting. That analysis provided valuable comparative estimates across molecularly defined subgroups. However, several important gaps remained.\u003c\/p\u003e\n\n\u003cp\u003eFirst, the earlier literature search was limited to January 2025. It therefore predated reporting of FZOCUS-1, a phase III randomized controlled trial evaluating fuzuloparib. Fuzuloparib is a PARP inhibitor that had not previously been incorporated into any network meta-analysis.\u003c\/p\u003e\n\n\u003cp\u003eSecond, the clinically distinct subpopulation of HRD-positive non-BRCA-mutated patients was not separately analyzed. This group has considerable therapeutic uncertainty.\u003c\/p\u003e\n\n\u003cp\u003eThird, the potential effect-modifying role of frontline bevacizumab background therapy on the comparative efficacy of maintenance strategies had not been systematically explored.\u003c\/p\u003e\n\n\u003cp\u003eFourth, the evolving biomarker-directed framework reflected in the 2026 NCCN Guidelines had not been incorporated as an analytical and interpretive context.\u003c\/p\u003e\n\n\u003cp\u003eNetwork meta-analysis allows simultaneous integration of direct and indirect evidence across multiple competing strategies within a unified statistical framework. An updated analysis incorporating these advances was therefore warranted.\u003c\/p\u003e\n\n\u003cp\u003eAccordingly, the researchers conducted an updated systematic review and network meta-analysis of randomized controlled trials. The trials compared first-line maintenance strategies for newly diagnosed advanced ovarian cancer. The literature search was extended to April 2026. The analysis incorporated the most recently available trial data, including FZOCUS-1. It was conducted within the biomarker-directed framework of the 2026 NCCN Guidelines.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers compared PARP inhibitor monotherapy, PARP inhibitor plus antiangiogenic therapy, and control across five molecularly defined populations:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eIntention-to-treat (the entire study population, regardless of biomarker status)\u003c\/li\u003e\n\u003cli\u003eBRCA-mutated (BRCAm)\u003c\/li\u003e\n\u003cli\u003eHRD-positive\u003c\/li\u003e\n\u003cli\u003eHRD-positive non-BRCAm\u003c\/li\u003e\n\u003cli\u003eHomologous recombination proficient (HRP)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers also performed prespecified subgroup analyses stratified by frontline bevacizumab background. These analyses explored whether bevacizumab exposure might modify the efficacy of maintenance treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis systematic review and network meta-analysis was conducted according to the PRISMA-NMA statement, an internationally accepted reporting standard. The protocol was registered in PROSPERO, a public database of systematic review protocols, under identifier CRD420261382266.\u003c\/p\u003e\n\n\u003cp\u003eEligible studies were phase III randomized controlled trials. They enrolled adults with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. All patients had achieved complete or partial response after first-line platinum-based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eTrials were included if they evaluated first-line maintenance therapy with a PARP inhibitor, either as monotherapy or in combination with antiangiogenic therapy. The trials also had to report progression-free survival hazard ratios with 95% confidence intervals, or provide sufficient data for estimation. These data were required in the intention-to-treat population, in molecularly defined subgroups, or in both.\u003c\/p\u003e\n\n\u003cp\u003eEligible interventions included PARP inhibitor monotherapy and PARP inhibitor plus antiangiogenic therapy. Comparators included placebo, observation, antiangiogenic maintenance, or protocol-defined maintenance controls. These controls included bevacizumab-containing controls where applicable.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers excluded trials of recurrent disease, platinum-sensitive or platinum-resistant relapse, and non-epithelial ovarian cancer. They also excluded trials limited to early-stage disease. They excluded trials in which PARP inhibitors were started concurrently with chemotherapy rather than as maintenance. They excluded PARP inhibitor combinations in which the independent contribution of PARP inhibition could not be isolated.\u003c\/p\u003e\n\n\u003cp\u003eNon-randomized studies, single-arm studies, phase I studies, reviews, editorials, case reports, and duplicate reports without additional relevant data were also excluded.\u003c\/p\u003e\n\n\u003cp\u003eWhen multiple reports of the same trial were available, the researchers used the most complete and most recent dataset. They used supplementary reports for additional subgroup, follow-up, or safety information.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers searched PubMed\/MEDLINE, Embase, Web of Science Core Collection, and ClinicalTrials.gov from database inception to 1 April 2026. They also screened major oncology conference proceedings, including ASCO, ESMO, SGO, and IGCS.\u003c\/p\u003e\n\n\u003cp\u003eSearch strategies combined terms for epithelial ovarian, fallopian tube, and primary peritoneal cancer. Search strategies combined terms for PARP inhibitors and first-line maintenance therapy. Search strategies combined terms for newly diagnosed disease and platinum-based chemotherapy. Search strategies combined terms for randomized phase III trials and placebo-controlled or double-blind designs. Search strategies combined relevant trial names. Supplementary trial-name searches were performed to identify primary reports, updated analyses, subgroup analyses, and conference abstracts.\u003c\/p\u003e\n\n\u003cp\u003eAfter duplicate removal, two reviewers independently screened titles, abstracts, and full texts. Disagreements were resolved by discussion or consultation with a third reviewer.\u003c\/p\u003e\n\n\u003cp\u003eTwo reviewers independently extracted study characteristics, patient and disease features, biomarker definitions, HRD assay methods, frontline bevacizumab exposure, intervention and comparator regimens, follow-up duration, and efficacy and safety outcomes.\u003c\/p\u003e\n\n\u003cp\u003ePFS hazard ratios and 95% confidence intervals were extracted for the intention-to-treat, BRCA-mutated, HRD-positive, HRD-positive non-BRCAm, and HRP populations when available. If several data cutoff points were reported, the researchers used the most mature estimate for the same population and assessment method.\u003c\/p\u003e\n\n\u003cp\u003ePFS estimates based on blinded independent central review or investigator assessment were extracted according to the primary reporting method of each trial. Safety data were extracted from the safety population defined in each trial. Safety outcomes included grade 3 or higher adverse events, adverse events leading to treatment discontinuation, and selected grade 3 or higher hematologic toxicities (blood-related side effects).\u003c\/p\u003e\n\n\u003cp\u003eRisk of bias was assessed using the Cochrane Risk of Bias 2 tool.\u003c\/p\u003e\n\n\u003cp\u003eThe primary efficacy outcomes were PFS in the HRD-positive and BRCAm populations. Secondary efficacy outcomes were PFS in the HRD-positive non-BRCAm, intention-to-treat, and HRP populations. The primary safety outcome was grade 3 or higher adverse events. Additional safety outcomes included treatment discontinuation due to adverse events and selected grade 3 or higher hematologic toxicities.\u003c\/p\u003e\n\n\u003cp\u003ePFS was analyzed using hazard ratios, and safety outcomes were analyzed using risk ratios. For PFS, a hazard ratio less than 1 favored the experimental regimen. For safety outcomes, a risk ratio greater than 1 indicated higher toxicity risk.\u003c\/p\u003e\n\n\u003cp\u003eSeparate networks were constructed for each efficacy population and safety outcome. Nodes were defined at the regimen level rather than by drug class. In the primary connected efficacy networks, placebo served as the common comparator.\u003c\/p\u003e\n\n\u003cp\u003eThe intention-to-treat, HRD-positive, and HRP networks included placebo, niraparib, rucaparib, senaparib, fuzuloparib, and fuzuloparib plus apatinib. The BRCAm network additionally included olaparib. The HRD-positive non-BRCAm network included placebo, niraparib, rucaparib, and senaparib.\u003c\/p\u003e\n\n\u003cp\u003eDirect active-to-active evidence was limited to the fuzuloparib plus apatinib versus fuzuloparib comparison in FZOCUS-1. Other active-regimen comparisons were informed indirectly through placebo.\u003c\/p\u003e\n\n\u003cp\u003ePAOLA-1 met the eligibility criteria for the systematic review. However, both treatment arms in PAOLA-1 received bevacizumab as mandatory background therapy. The control arm was bevacizumab-containing rather than placebo alone. Because of this, PAOLA-1 was eligible for the systematic review but was not incorporated into the primary placebo-controlled connected network meta-analyses for efficacy. Its treatment comparison formed a disconnected network component. The trial was summarized narratively and considered only in descriptive contextual analyses where appropriate. PAOLA-1 was also excluded from the main safety network meta-analysis to maintain consistency with the placebo-controlled network structure.\u003c\/p\u003e\n\n\u003cp\u003eNetwork meta-analyses were performed within connected networks using a frequentist framework. Log hazard ratios and corresponding standard errors were used for PFS, and log risk ratios were used for dichotomous safety outcomes. Random-effects models were used given expected clinical and methodological heterogeneity across trials. Relative effects were reported with 95% confidence intervals, and treatment rankings were summarized using P-scores as supportive measures.\u003c\/p\u003e\n\n\u003cp\u003eTransitivity was considered by comparing key trial characteristics across comparisons. These characteristics included biomarker-defined populations, HRD testing methods, bevacizumab exposure, comparator regimens, and PFS assessment methods. Because networks were largely placebo-centered and active-to-active evidence was sparse, indirect comparisons among active regimens were interpreted cautiously. Heterogeneity was assessed using t² and, where applicable, I². Formal inconsistency testing was limited to networks with suitable closed loops.\u003c\/p\u003e\n\n\u003cp\u003eAn exploratory study-level effect-modification analysis assessed whether frontline bevacizumab background modified the PFS benefit of PARP inhibitor-based maintenance. Trials were categorized as requiring, allowing, or not allowing frontline bevacizumab. Pooled hazard ratios were estimated within these categories. Differences were explored using meta-regression models with bevacizumab background as a categorical and continuous variable. These analyses were considered hypothesis-generating because of limited trial numbers, ecological study-level covariates, and heterogeneity within categories.\u003c\/p\u003e\n\n\u003cp\u003eSensitivity analyses compared results with and without FZOCUS-1, which introduced fuzuloparib-based regimens and the only direct active-treatment comparison. Additional regimen-specific analyses evaluated individual PARP inhibitor monotherapies across the intention-to-treat, HRD-positive, BRCAm, HRD-positive non-BRCAm, and HRP populations where data were available.\u003c\/p\u003e\n\n\u003cp\u003eSafety network meta-analyses were performed for connected regimens with sufficient data, using placebo as the common comparator where possible. Grade 3 or higher adverse events were defined according to the Common Terminology Criteria for Adverse Events (CTCAE) grading system, using the CTCAE version reported in each original trial. Because safety data for combination regimens were sparse and not consistently connected, comparative safety between PARP inhibitor monotherapy and PARP inhibitor–antiangiogenic combinations was considered uncertain. Safety findings from disconnected bevacizumab-background comparisons, including PAOLA-1, were summarized descriptively rather than included in the primary safety network meta-analysis. Because safety outcomes were analyzed in the overall safety populations rather than molecular subgroups, safety network structures differed from efficacy subgroup networks.\u003c\/p\u003e\n\n\u003ch2 id=\"results\"\u003eKey Findings: What the Analysis Showed\u003c\/h2\u003e\n\n\u003cp\u003eSeven phase III randomized, double-blind trials involving 3,930 patients were included in the systematic review. Six trials contributed to the primary placebo-controlled connected efficacy networks. PAOLA-1 was excluded from the primary network for the reasons detailed in the Methods section.\u003c\/p\u003e\n\n\u003cp\u003eFour trials were international multicenter studies: SOLO-1, PAOLA-1, PRIMA, and ATHENA-MONO. Three trials were conducted in China: PRIME, FLAMES, and FZOCUS-1.\u003c\/p\u003e\n\n\u003cp\u003eInterventions included PARP inhibitor monotherapy and PARP inhibitor plus antiangiogenic therapy. Background frontline bevacizumab exposure varied across trials. PAOLA-1 required bevacizumab. ATHENA-MONO included some prior bevacizumab exposure. SOLO-1, PRIME, PRIMA, and FLAMES excluded frontline bevacizumab per protocol. In FZOCUS-1, 6.7% of patients had received bevacizumab during frontline chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003ePFS was assessed by blinded independent central review in FZOCUS-1, PRIMA, PRIME, and FLAMES. PFS was assessed by investigator review in SOLO-1, PAOLA-1, and ATHENA-MONO.\u003c\/p\u003e\n\n\u003cp\u003eRisk of bias was evaluated using the Cochrane Risk of Bias 2 tool. All included trials were classified as low risk of bias overall, with no domain showing substantial concerns. Specifically, the randomization process, deviations from intended interventions, missing outcome data, outcome measurement, and selection of the reported result were all judged to be at low risk.\u003c\/p\u003e\n\n\u003cp\u003eSeparate PFS networks were generated for the intention-to-treat, HRD-positive, BRCAm, HRD-positive non-BRCAm, and HRP populations. Placebo was the common comparator across all connected networks.\u003c\/p\u003e\n\n\u003cp\u003eThe intention-to-treat, HRD-positive, and HRP networks included placebo, niraparib, rucaparib, senaparib, fuzuloparib, and fuzuloparib plus apatinib. The BRCAm network additionally included olaparib. The HRD-positive non-BRCAm network was more limited, including only placebo, niraparib, rucaparib, and senaparib. No fuzuloparib or fuzuloparib plus apatinib data were available for this subgroup.\u003c\/p\u003e\n\n\u003cp\u003eDirect active-to-active evidence was sparse. The only direct head-to-head comparison between active regimens was fuzuloparib plus apatinib versus fuzuloparib from FZOCUS-1. All other active treatment comparisons relied on indirect evidence through placebo.\u003c\/p\u003e\n\n\u003ch2 id=\"hrd\"\u003eResults in the HRD-Positive Population\u003c\/h2\u003e\n\n\u003cp\u003eIn the HRD-positive connected placebo-controlled network, all evaluated PARP inhibitor-based maintenance regimens significantly improved PFS compared with placebo.\u003c\/p\u003e\n\n\u003cp\u003eThe estimated hazard ratios versus placebo were:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFuzuloparib plus apatinib:\u003c\/strong\u003e 0.67 (95% confidence interval, 0.48–0.94)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFuzuloparib:\u003c\/strong\u003e 0.62 (95% confidence interval, 0.44–0.86)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRucaparib:\u003c\/strong\u003e 0.47 (95% confidence interval, 0.31–0.72)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNiraparib:\u003c\/strong\u003e 0.45 (95% confidence interval, 0.36–0.57)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSenaparib:\u003c\/strong\u003e 0.36 (95% confidence interval, 0.22–0.60)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA hazard ratio below 1 means the treatment reduced the risk of cancer progression or death compared with placebo. For example, a hazard ratio of 0.45 for niraparib means the risk of progression or death was 55% lower than with placebo during the study period.\u003c\/p\u003e\n\n\u003cp\u003eBased on P-scores, which rank treatments by their relative performance across the network, senaparib ranked highest. Niraparib ranked second, followed by rucaparib, fuzuloparib, fuzuloparib plus apatinib, and placebo.\u003c\/p\u003e\n\n\u003cp\u003eAmong active regimens, no statistically significant difference was observed between fuzuloparib plus apatinib and fuzuloparib monotherapy. The network hazard ratio was 1.31 (95% confidence interval, 0.77–2.24). However, this result should be interpreted as an absence of conclusive evidence for an incremental PFS benefit within the connected network. It should not be interpreted as evidence that the combination provides no additional benefit.\u003c\/p\u003e\n\n\u003cp\u003eThis comparison was largely informed by FZOCUS-1, which evaluated fuzuloparib plus apatinib. The limited adoption of this regimen outside selected geographic settings may restrict how well this finding applies to other PARP inhibitor–antiangiogenic combinations.\u003c\/p\u003e\n\n\u003cp\u003eThe indirect comparison favored senaparib over fuzuloparib plus apatinib, with a hazard ratio of 1.87 (95% confidence interval, 1.02–3.43).\u003c\/p\u003e\n\n\u003ch2 id=\"brcam\"\u003eResults in the BRCA-Mutated Population\u003c\/h2\u003e\n\n\u003cp\u003eIn the BRCAm population, all PARP inhibitor-based regimens included in the connected network significantly prolonged PFS compared with placebo. Treatment effects were generally larger in this population than in other groups.\u003c\/p\u003e\n\n\u003ch2 id=\"other-groups\"\u003eResults in Other Molecular Groups\u003c\/h2\u003e\n\n\u003cp\u003ePARP inhibitor monotherapy also significantly improved PFS in the HRD-positive non-BRCA-mutated population. This finding supports the clinical relevance of HRD status beyond BRCA mutation alone. In other words, testing for HRD can identify patients who may benefit from PARP inhibitors even when they do not carry a BRCA mutation.\u003c\/p\u003e\n\n\u003cp\u003eBenefit in the intention-to-treat population was smaller than in biomarker-selected populations. This means that when all patients are analyzed together regardless of biomarker status, the average benefit appears smaller than in the groups selected for BRCA mutations or HRD.\u003c\/p\u003e\n\n\u003cp\u003eEvidence of benefit in the homologous recombination proficient (HRP) population was inconsistent. HRP means the tumor does not have the specific DNA repair defect that makes PARP inhibitors most effective.\u003c\/p\u003e\n\n\u003cp\u003eIndirect comparisons showed no statistically significant superiority of one active regimen over another. Within the connected network, no statistically significant incremental PFS benefit was established for adding antiangiogenic therapy to PARP inhibition. This comparison was limited by the restricted evidence base for combination therapy and by the inability to incorporate PAOLA-1 into the primary network because of network disconnection.\u003c\/p\u003e\n\n\u003ch2 id=\"bevacizumab\"\u003eDoes Prior Bevacizumab Change the Benefit?\u003c\/h2\u003e\n\n\u003cp\u003eNo statistically significant evidence indicated that frontline bevacizumab exposure modified the relative PFS benefit of PARP inhibitor-based maintenance. Overall, bevacizumab background was not identified as a statistically significant effect modifier, although interaction signals were seen in the HRD-positive and HRP populations; the researchers consider these findings hypothesis-generating.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the researchers note that these analyses were hypothesis-generating. They were limited by the small number of trials, the use of study-level rather than patient-level data, and differences between trials within each category.\u003c\/p\u003e\n\n\u003cp\u003eSensitivity analyses yielded results consistent with the primary analysis. This means the main findings held up when the researchers tested them in different ways.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSafety Findings\u003c\/h2\u003e\n\n\u003cp\u003ePARP inhibitor monotherapy increased grade 3 or higher adverse events compared with placebo. Grade 3 or higher adverse events are side effects that are serious or severe.\u003c\/p\u003e\n\n\u003cp\u003eComparative safety of combination regimens remained limited. Because safety data for combination regimens were sparse and not consistently connected across trials, the comparative safety between PARP inhibitor monotherapy and PARP inhibitor–antiangiogenic combinations was considered uncertain.\u003c\/p\u003e\n\n\u003cp\u003eSafety findings from disconnected bevacizumab-background comparisons, including PAOLA-1, were summarized descriptively rather than included in the primary safety network meta-analysis.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis network meta-analysis supports biomarker-directed PARP inhibitor-based first-line maintenance in advanced ovarian cancer. The greatest PFS benefit was seen in BRCA-mutated and HRD-positive populations.\u003c\/p\u003e\n\n\u003cp\u003eFor patients, this means that knowing your BRCA mutation status and HRD status is important. These biomarker results help your care team identify which maintenance strategy is most likely to benefit you.\u003c\/p\u003e\n\n\u003cp\u003eNo active regimen demonstrated statistically significant superiority within the connected network. This means the analysis could not prove that any one PARP inhibitor or combination is clearly better than another when compared indirectly.\u003c\/p\u003e\n\n\u003cp\u003eThe incremental benefit of adding antiangiogenic therapy to PARP inhibition remains uncertain. This uncertainty exists because connected-network evidence for combination strategies was limited, and PAOLA-1 could not be incorporated into the primary network.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers emphasize that these findings should not be interpreted as evidence against the clinical value of olaparib plus bevacizumab or combination maintenance strategies in general. The analysis simply could not draw firm conclusions about the added benefit of combination therapy within the connected network.\u003c\/p\u003e\n\n\u003cp\u003eTreatment selection should integrate several factors:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMolecular status (BRCA mutation and HRD status)\u003c\/li\u003e\n\u003cli\u003ePrior bevacizumab exposure\u003c\/li\u003e\n\u003cli\u003eSafety and tolerability\u003c\/li\u003e\n\u003cli\u003eTreatment availability\u003c\/li\u003e\n\u003cli\u003ePatient preference\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eSeveral limitations affect how these findings should be interpreted.\u003c\/p\u003e\n\n\u003cp\u003eFirst, direct active-to-active evidence was sparse. The only direct head-to-head comparison between active regimens was fuzuloparib plus apatinib versus fuzuloparib from a single trial. All other active treatment comparisons relied on indirect evidence through placebo. Indirect comparisons are less reliable than direct comparisons.\u003c\/p\u003e\n\n\u003cp\u003eSecond, PAOLA-1 could not be incorporated into the primary placebo-controlled connected network. Both treatment arms in PAOLA-1 received bevacizumab as mandatory background therapy, and the control arm was bevacizumab-containing rather than placebo alone. This created a disconnected network component.\u003c\/p\u003e\n\n\u003cp\u003eThird, the comparison between fuzuloparib plus apatinib and fuzuloparib monotherapy was largely informed by FZOCUS-1. The limited adoption of this regimen outside selected geographic settings may restrict how well the finding applies to other PARP inhibitor–antiangiogenic combinations.\u003c\/p\u003e\n\n\u003cp\u003eFourth, the bevacizumab effect-modification analyses were hypothesis-generating. They were limited by small trial numbers, study-level rather than patient-level covariates, and heterogeneity within categories.\u003c\/p\u003e\n\n\u003cp\u003eFifth, safety data for combination regimens were sparse and not consistently connected. Comparative safety between PARP inhibitor monotherapy and combination therapy remains uncertain.\u003c\/p\u003e\n\n\u003cp\u003eSixth, the HRD-positive non-BRCAm network was limited. It included only placebo, niraparib, rucaparib, and senaparib. No fuzuloparib or fuzuloparib plus apatinib data were available for this subgroup.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Questions to Ask Your Care Team\u003c\/h2\u003e\n\n\u003cp\u003eBased on this analysis, patients with newly diagnosed advanced ovarian cancer may want to discuss the following with their care team:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003eHas my tumor been tested for BRCA1 and BRCA2 mutations?\u003c\/li\u003e\n\u003cli\u003eHas my tumor been tested for homologous recombination deficiency (HRD) status?\u003c\/li\u003e\n\u003cli\u003eWhich molecular group do I fall into, and what does that mean for my maintenance treatment options?\u003c\/li\u003e\n\u003cli\u003eDid I receive bevacizumab during my initial chemotherapy, and does that affect my maintenance options?\u003c\/li\u003e\n\u003cli\u003eWhat are the potential benefits and risks of PARP inhibitor monotherapy versus combination therapy in my situation?\u003c\/li\u003e\n\u003cli\u003eWhat side effects should I watch for, and how will they be managed?\u003c\/li\u003e\n\u003cli\u003eWhich maintenance strategies are available and covered by insurance in my region?\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe researchers conclude that treatment selection should integrate molecular status, prior bevacizumab exposure, safety, treatment availability, and patient preference. This is a shared decision between the patient and the care team.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is PARP inhibitor maintenance therapy for ovarian cancer?\u003c\/h3\u003e\n\u003cp\u003eMaintenance therapy is treatment given after initial chemotherapy has shrunk the cancer, aiming to delay its growth or return. PARP inhibitors are drugs that block a protein cancer cells use to repair their DNA. They work particularly well in tumors that already have impaired DNA repair, such as those with BRCA mutations or homologous recombination deficiency (HRD).\u003c\/p\u003e\n\u003ch3\u003eWhat does a hazard ratio below 1 mean in this context?\u003c\/h3\u003e\n\u003cp\u003eA hazard ratio below 1 means the treatment reduced the risk of cancer progression or death compared with placebo during the study period. For example, a hazard ratio of 0.45 for niraparib in the HRD-positive population means the risk of progression or death was 55% lower than with placebo. Lower numbers indicate a larger reduction in risk.\u003c\/p\u003e\n\u003ch3\u003eDoes adding antiangiogenic therapy to a PARP inhibitor improve outcomes?\u003c\/h3\u003e\n\u003cp\u003eIn this analysis, no statistically significant incremental progression-free survival benefit was established for adding antiangiogenic therapy to PARP inhibition within the connected network. However, this should not be interpreted as evidence that the combination provides no additional benefit. The comparison was limited by sparse direct evidence, and one major trial could not be included in the primary network.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects are associated with PARP inhibitor maintenance?\u003c\/h3\u003e\n\u003cp\u003ePARP inhibitor monotherapy increased grade 3 or higher adverse events compared with placebo. Grade 3 or higher means side effects that are serious or severe. The comparative safety of combining a PARP inhibitor with antiangiogenic therapy remained uncertain because safety data for combination regimens were sparse and not consistently connected across trials. Discuss specific side effects and their management with your care team.\u003c\/p\u003e\n\u003ch3\u003eDoes prior bevacizumab treatment change how well maintenance works?\u003c\/h3\u003e\n\u003cp\u003eNo statistically significant evidence indicated that frontline bevacizumab exposure modified the relative progression-free survival benefit of PARP inhibitor-based maintenance. Overall, the analysis did not find that bevacizumab during initial treatment changed the benefit of maintenance, although signals were seen in the HRD-positive and HRP populations. However, these analyses were hypothesis-generating and limited by small trial numbers and study-level data.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my care team about maintenance therapy?\u003c\/h3\u003e\n\u003cp\u003eYou may want to ask: Has my tumor been tested for BRCA1 and BRCA2 mutations and for homologous recombination deficiency (HRD) status? Which molecular group do I fall into, and what does that mean for my maintenance options? Did I receive bevacizumab during initial chemotherapy, and does that affect my options? What are the benefits and risks of monotherapy versus combination therapy in my situation?\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with newly diagnosed advanced ovarian cancer seek a second opinion about PARP inhibitor maintenance therapy?\u003c\/h3\u003e\n\u003cp\u003eA second opinion can help when biomarker results are unclear or when more than one maintenance option is being considered. BRCA mutation and HRD status determine which PARP inhibitor strategies are likely to help, and benefit is smaller in the intention-to-treat population and inconsistent in HRP tumors. Whether adding antiangiogenic therapy to a PARP inhibitor provides extra benefit remains uncertain, and prior bevacizumab exposure may factor into selection. Because no active regimen proved superior to another, reviewing molecular status, safety, availability and preference with another expert is reasonable. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Feng J, Qin X, Mo X.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliation:\u003c\/strong\u003e Department of Gynecology and Obstetrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, China\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Oncology\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Published 18 September 2026; DOI 10.3389\/fonc.2026.1884407\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSystematic review registration:\u003c\/strong\u003e PROSPERO, identifier CRD420261382266\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle type:\u003c\/strong\u003e Systematic Review\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace personalized medical advice. Patients should discuss their individual treatment options with their oncology care team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":48074012950684,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/sv\/products\/parp-inhibitor-maintenance-therapy-for-newly-diagnosed-advanced-ovarian-cancer-what-a-major-review-of-seven-trials-found","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}